JAK Archives - Medical Conferences

JAK1 inhibitor shows promising long-term efficacy in PN

Presented By

Dr Shawn Kwatra, Johns Hopkins University School of Medicine, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:44

Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Trial

Phase 3, DELTA FORCE

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:33

Deuruxolitinib significantly improves hair satisfaction in AA

Presented By

Dr Paradi Mirmirani, Kaiser Permanente Vallejo Medical Center, USA

Trial

THRIVE-AA

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:56

Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:51

Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:28

Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?

Presented By

Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, MANIFEST-2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:28

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

New JAK1 inhibitor outperforms placebo in active RA

Presented By

Dr Jinjing Liu, Peking Union Medical College Hospital, China

Trial

Phase 3

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:37

Is JAK inhibition the right choice for patients with relapsing giant cell arteritis?

Presented By

Dr Fernando López Gutiérrez, University Hospital Ramón y Cajal, Spain

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:33

Giant cell arteritis: Upadacitinib may be an upcoming treatment option

Presented By

Prof. Daniel Blockmans, University Hospitals Leuven, Belgium

Trial

Phase 3, SELECT-GCA

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:33

JAK inhibitors have similar incidence rates of long-term adverse events as traditional immunomodulators

Presented By

Olivia Lamberg, University of Michigan, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:52

Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

BRAVE-AA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:43

Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, MA, USA

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:16

Delgocitinib cream: A promising treatment option for chronic hand eczema

Presented By

Prof. Melinda Gooderham, Queens University, Canada

Trial

Phase 3, DELTA 3

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:31

Biologicals and JAK inhibitors hold promise in microscopic colitis

Presented By

Dr Bram Verstockt, University Hospitals Leuven, Belgium

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:35

Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial

Presented By

Dr Séverine Vermeire, University Hospitals Leuven, Belgium

Trial

Phase 2, PIZZICATO

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:28

U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease

Presented By

Dr Geert D’Haens, Amsterdam University Medical Centers, the Netherlands

Trial

U-ENDURE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:25

TRIUMPH: Tofacitinib as rescue option for acute severe ulcerative colitis

Presented By

Dr Neeraj Narula, McMaster University, Canada

Trial

Phase 2, TRIUMPH

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:23

Momelotinib beats controls regarding transfusion outcomes in myelofibrosis

Presented By

Prof. Ruben Mesa, Wake Forest Baptist Comprehensive Cancer Center, NC, USA

Trial

Phase 3, Simplify-1, MOMENTUM

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled

Presented By

Prof. Séverine Vermeire, UZ Leuven, Belgium

Trial

Phase 3, DESTINY1

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:48

Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease

Presented By

Prof. Jean-Frederic Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-EXCEED; U-EXCEL

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:27

Upadacitinib provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, Measure Up; AD UP

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:39

JAK1 inhibition: a promising forthcoming treatment option in vitiligo

Presented By

Prof. Khaled Ezzedine, University Paris-Est Créteil, France

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:17

JAK3/TEC inhibition achieves clinically meaningful responses in AA

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:31

JAK inhibitors for AD in the real world

Presented By

Dr Yik Weng, National Skin Centre, Singapore

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:02

Novel JAK1 inhibitor for patients with atopic dermatitis

Presented By

Jianzhong Zhang, Peking University People’s Hospital, China

Trial

Phase 3, QUARTZ3

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:00

Patients with AA report high long-term regrowth rates with baricitinib

Presented By

Dr Maryanne Senna, Harvard Medical School, MA, USA

Trial

BRAVE-AA1 and BRAVE-AA2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:22

Can ritlecitinib deliver long-term efficacy in alopecia areata?

Presented By

Prof. Melissa Piliang, Cleveland Clinic, OH, USA

Trial

Phase 3, ALLEGRO

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:18

Cardiovascular safety of JAK inhibitors: reassuring results from a real-world study

Presented By

Mr Romain Aymon, Geneva University Hospital, Switzerland

Trial

ORAL Surveillance

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 00:00

New developments in steroid-refractory acute GvHD

Presented By

Prof. Ronjon Chakraverty, University of Oxford, UK

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:54

Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure

Presented By

Dr Brian Feagan, Western University, Canada

Trial

Phase 3, U-EXCEL, U-EXCEED, U-ENDURE

Conference

DDW 2023

Type

News article

13 June 2023 13:50

JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

Presented By

Dr Maryanne Senna, Lahey Hospital and Medical Center, MA, USA

Trial

Phase 3, THRIVE-AA1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:41

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:51

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:43

Delgocitinib shows promise as topical therapy for chronic hand eczema

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, DELTA 1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:58

Lichen planus: a future indication for baricitinib?

Presented By

Ms Angelina Hwang , Mayo Clinic College of Medicine, AZ, USA

Trial

Phase 2

Conference

AAD

Type

Peer-reviewed article

15 May 2023 09:58

Eligibility and selection of JAK inhibitors for constitutional eczema

Presented By

Dr Dirk Jan Hijnen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:57

The rise of JAK inhibitors for alopecia areata

Presented By

Dr Brett King, Yale University, CT, USA

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:47

Upadacitinib successful in the management of both CD and UC

Presented By

Dr Brian Feagan , University of Western Ontario, Canada

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 15:40

Solid results for long-term therapy of UC with filgotinib

Presented By

Dr Brian Feagan, University of Western Ontario, Canada

Trial

Phase 3, SELECTION

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 15:01

Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN

Presented By

Dr Nabih Maslah, Université Paris Cité, France

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:43

Upadacitinib for CD: remarkable efficacy in induction therapy

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 3, U-EXCEL

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:42

Start low with brepocitinib and ritlecitinib in UC

Presented By

Dr Kenneth Hung, Pfizer, MA, USA

Trial

Phase 2, VIBRATO

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:34

New analysis assesses the safety of tofacitinib regarding extended MACE

Presented By

Prof. Maya Buch, University of Manchester, United Kingdom

Trial

ORAL Surveillance

Conference

ACR 2022

Type

News article

1 December 2022 14:18

Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise

Presented By

Prof. Alexandra Kimball, Harvard Medical School, MA, USA

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:03

Long-term improvement in alopecia areata with ritlecitinib therapy

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:30

Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata

Presented By

Prof. Brett King, Yale University School of Medicine, CT, USA

Trial

Phase 3, THRIVE-AA1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:18

Baricitinib possible therapeutic option for children with AD

Presented By

Dr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain

Trial

Phase 3, BREEZE-AD-PEDS

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:15

No adverse pregnancy outcomes in patients exposed to baricitinib

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:47

Alopecia areata: light at the end of the tunnel

Presented By

Prof. Maryanne Senna , Harvard Medical School, MA, USA

Trial

Phase 3, BRAVE-AA1, BRAVE-AA2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:01

Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib

Presented By

Prof. Lars Erik Kristensen , Copenhagen University Hospital, Denmark

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:30

A novel oral treatment possibility for non-radiographic axSpA on the horizon

Presented By

Prof. Filip van den Bosch , Ghent University, Belgium

Trial

Phase 3, SELECT-AXIS 2

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:17

VTE in global registry data more common in JAK inhibitor-treated RA patients

Presented By

Prof. Adeline Ruyssen-Witrand, Toulouse University Hospital, France

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:52

Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis

Presented By

Prof. Athimalaipet Ramanan , Bristol Medical School, United Kingdom

Trial

Phase 3, JUVE-BASIS

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:22

Momelotinib induces a rapid and sustained improvement in haemoglobin levels in patients with myelofibrosis

Presented By

Prof. Srdan Verstovsek, University of Texas MD Anderson Cancer Center, TX, USA

Trial

Phase 3, MOMENTUM

Conference

EHA 2022

Type

News article

1 July 2022 11:19

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, Heads Up

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:35

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:12

JAK inhibition offers promising treatment prospects for uncommon dermatoses

Presented By

Prof. Matthew Vesely, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:48

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By

Prof. William Damsky, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:12

Light at the end of the tunnel for vitiligo therapy

Presented By

Dr David Rosmarin, Tufts Medical Center, USA

Trial

Phase 3, TRuE-V1; TRuE-V2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:05

JAK inhibitors: A risk assessment

Presented By

Prof. Brett King, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:59

Monitoring is key during JAK inhibitor therapy

Presented By

Prof. Jonathan Silverberg

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:47

Alopecia areata: 1-year baricitinib treatment increases success

Presented By

Prof. Brett King, Yale School of Medicine, USA

Trial

Phase 3, BRAVE-AA1; BRAVE-AA2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:35

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:44

Combined endpoint may support personalised medicine in ulcerative colitis

Presented By

Prof. Stefan Schreiber, Christian-Albrecht University, Germany

Trial

Phase 3, SELECTION

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:06

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Trial

Phase 2, DIVERGENCE 2

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:04

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, U-ACHIEVE

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:57

Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Presented By

Prof. Jean-Frédéric Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-ACHIEVE; U-ACCOMPLISH

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:53

Upadacitinib effector pathways unravelled

Presented By

Dr Bram Verstockt, KU Leuven, Belgium

Trial

Phase 2, U-ACHIEVE

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:49

Inhibition of heat shock protein: A novel way to treat psoriasis?

Presented By

Dr Anne Bregnhøj, Aarhus University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:02

IL-17 inhibition showing efficacy in GCA in phase 2 trials

Presented By

Prof. Jens Thiel, Medical University Graz, Austria

Trial

Phase 2, TitAIN

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:05

Cycling JAK inhibitors shows similar effectiveness to switching to a bDMARD in difficult-to-treat RA

Presented By

Dr Manuel Pombo-Suarez, Hospital Clinico Universitario de Santiago De Compostela, Spain

Trial

JAK-pot

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:03

Superior EASI scores after switch from dupilumab to upadacitinib

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:34

Novel JAK3/TEC blocker leads to maintained re-pigmentation in vitiligo

Presented By

Prof. Khaled Ezzedine, University Hospital Henri Mondor, France

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:32

Topical JAK1/JAK2 inhibitor effective in vitiligo

Presented By

Dr David Rosmarin, Tufts Medical Center Boston, USA

Trial

Phase 3, TRuE-V1; TruE-V2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:27

Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, JADE DARE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:26

Ruxolitinib cream: a safe treatment for elderly AD patients

Presented By

Prof. Jacek Szepietowksi, Wroclaw Medical University, Poland

Trial

Phase 3, TRuE-AD1; TRuE-AD2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:21

Novel and upcoming targeted AD treatment

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

ECZTRA 3; Measure Up; ADVISE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:20

Existing and upcoming small molecules in psoriasis

Presented By

Dr Enikö Sonkoly , Karolinska University Hospital, Sweden

Trial

POETYK PSO; PSOARING

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:19

JAK1/2: A promising novel treatment target in alopecia areata

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

Phase 3, BRAVE-AA1; BRAVE-AA2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:12

Alopecia areata: encouraging response rates with JAK3/TEC inhibition

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

ALLEGRO

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:11

Upadacitinib efficacious and safe as maintenance therapy for UC

Presented By

Dr Remo Panaccione, University of Calgary, Canada

Trial

Phase 3, U-ACHIEVE, U-ACCOMPLISH

Conference

UEGW 2021

Type

News article

27 October 2021 10:06

Upadacitinib outperforms placebo in UC patients with inadequate response to biologics

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, U-ACHIEVE, U-ACCOMPLISH

Conference

UEGW 2021

Type

News article

27 October 2021 10:02

Rapid symptom control for UC patients on upadacitinib

Presented By

Dr Edward Loftus Jr, Mayo Clinic College of Medicine, MN, USA

Trial

Phase 3, U-ACHIEVE, U-ACCOMPLISH

Conference

UEGW 2021

Type

News article

27 October 2021 10:01

Filgotinib demonstrates promising results for various lines of therapy in UC

Presented By

Prof. Iris Dotan, Rabin Medical Center, Israel

Trial

Phase 3, SELECTION

Conference

UEGW 2021

Type

News article

27 October 2021 09:59

Filgotinib demonstrates long-term corticosteroid-sparing effects in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, SELECTION

Conference

UEGW 2021

Type

News article

27 October 2021 09:58

Long-term benefits of tofacitinib for substantial proportion of UC patients

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Trial

Phase 3, OCTAVE Sustain

Conference

UEGW 2021

Type

News article

27 October 2021 09:56

Ritlecitinib and brepocitinib are promising JAK inhibitors for UC

Presented By

Dr William Sandborn, University of California San Diego, CA, USA

Trial

Phase 2, VIBRATO

Conference

UEGW 2021

Type

News article

27 October 2021 09:53

Psoriatic arthritis: Guidelines and best practice

Trial

Phase 3, BE ACTIVE, PATERA

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:19

Novel targets in myelofibrosis: overview of emergent therapies

Presented By

Prof. Francesco Passamonti, University of Insubria, Italy

Trial

PERSIST; SIMPLIFY; BOREAS

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:54

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By

Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:53

Rituximab or JAK inhibitors increase the risk of severe COVID-19

Presented By

Dr Jeffrey Sparks, Brigham and Women’s Hospital, MA, USA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:36

SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis

Presented By

Dr Atul Deodhar, Oregon Health & Science University, OR, USA

Trial

SELECT-AXIS 1

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:25

JAK inhibitors and bDMARDs show comparable effectiveness

Presented By

Mr Andrei Barbulescu, Karolinska Institutet, Sweden

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 10:23

Allergies: an underrated factor in alopecia pathogenesis

Presented By

Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:45

Significant improvements in the system armamentarium for AD treatment

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:20

Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis

Presented By

Prof. Jonathan Silverberg, George Washington University, WA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:10

JAK inhibition as a treatment option for ankylosing spondylitis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:02

Persuasive long-term results for JAK inhibition in rheumatoid arthritis

Presented By

Prof. Josef Smolen, Medical University of Vienna, Austria

Trial

Phase 3, SELECT-MONOTHERAPY

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:00

Rheumatoid arthritis: new EULAR treatment guidelines

Presented By

Prof. Daniel Aletaha, Medical University Vienna, Austria

Trial

IDEA, NORD-STAR

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:00

COVID-19 in patients with rheumatic disease: most report mild disease

Presented By

Dr Akhil Sood, University of Texas Medical Branch, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:57

Baricitinib in AD: Efficacy paired with consistent long-term results

Presented By

Prof. Jonathan Silverberg , George Washington University, USA

Trial

Phase 3, BREEZE-AD3

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:31

JAK inhibitors in AA: re-establishing the immune privilege of hair follicles

Presented By

Prof. Taisuke Ito, Hamamatsu University School of Medicine, Japan

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:27

JAK inhibitors in vitiligo

Presented By

Dr Mehdi Rashighi, Massachusetts Medical School, USA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:26

JAK1 inhibition successful in hidradenitis suppurativa

Presented By

Dr Afsaneh Alavi , Mayo Clinic, USA

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:25

Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD

Presented By

Prof. Megan Landis, University of Louisville School of Medicine, USA

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:22

Light at the end of the tunnel for chronic hand eczema

Presented By

Prof. Margitta Worm, Prof. Howard Sofen

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:37

Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, Measure Up

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:24

Filgotinib effective as maintenance treatment for ulcerative colitis

Presented By

Prof. L Peyrin-Biroulet, Nancy University Hospital, France

Trial

Phase 3, SELECTION

Conference

UEGW 2020

Type

News article

2 November 2020 12:08

GRAVITAS-301: improved complete aGVDH response

Presented By

Prof. Robert Zeiser, University Hospital Freiburg, Germany

Trial

Phase 3, GRAVITAS-301

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 10:02

Baricitinib beneficial in head and neck AD

Presented By

Dr Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 3, BREEZE-AD1 and BREEZE-AD2

Conference

AAD 2020

Type

Peer-reviewed article

19 August 2020 07:23

COVID-19 and inflammatory rheumatic disease: some key issues

Presented By

Prof. G. Burmester, Charité University Hospital, Germany

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 15:06

Upadacitinib provides fast onset of improvement in psoriatic arthritis

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

SELECT-PsA-1

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 14:02

Pipeline of IBD drugs

Presented By

Prof. W. Sandborn, University of California San Diego, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 13:55

Clinical remission after dose escalation of upadacitinib

Presented By

Dr W. Sandborn & Dr S. Vermeire

Trial

Phase 2, CELEST, U-ACHIEVE

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 12:45

Filgotinib promising in RA patients naïve to methotrexate

Presented By

Prof. Rene Westhovens, University of Leuven, Belgium

Trial

Phase 3, FINCH 3

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:05

Sustained efficacy of monotherapy with upadacitinib after 48 weeks

Presented By

Prof. Joseph Smolen, Medical University of Vienna, Austria

Trial

SELECT-MONOTHERAPY

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 22:06

JAK1 inhibition shows remarkable efficacy in AS

Presented By

Prof. Désirée van der Heijde, Leiden University Medical Center, the Netherlands

Trial

Phase 3, SELECT-AXIS 1

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 20:57

Small molecules: interesting novel treatment options in AD

Presented By

Prof. Tilo Biedermann, Helmholtz Center Munich, German

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 20:27

Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata

Presented By

Dr James Cassella

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 18:54

JAK inhibition plus TCS lead to high clearance rates in AD

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Trial

Phase 3, BREEZE-AD7

Type

Peer-reviewed article

9 December 2019 16:53

Green light for a second JAK inhibitor in AD

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, JADE MONO-1

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 14:06

Topical ruxolitinib effective in vitiligo

Presented By

Prof. Amit Pandya, University of Texas Southwestern Medical Center, USA

Conference

EADV 2019

9 December 2019 13:08

Peficitinib likely efficacious and safe

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 20:42

Tofacitinib is safe according to real-world data analysis

Presented By

Dr Joel Kremer, Albany Medical College, New York, USA

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 18:51

Switching upadacitinib and adalimumab is beneficial in refractory RA

Trial

Phase 3, SELECT-COMPARE

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 17:54

Novel treatment options for many dermatologic indications

Presented By

Prof. Lone Sko; Prof. Lars Iversen

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 20:13

Long awaited oral therapy for moderate-to-severe AD

Presented By

Prof. Thomas Bieber, University Medical Center Bonn, Germany

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 19:14

Novel treatment options in alopecia areata and vitiligo

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 18:20

New targets and biologics for cutaneous lupus erythematosus

Presented By

Prof. Victoria P. Werth, University of Pennsylvania, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 15:59

Advances in target-oriented therapy: psoriatic arthritis

Presented By

Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland

Trial

ECLIPSA, TICOPA

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 23:48

Small molecules, apremilast, and TYK2

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Trial

ESTEEM, PALACE, LIBERATE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 09:45

Pan-Janus kinase inhibitor TD-1473

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 21:22

Upadacitinib: data from U-ACHIEVE and CELEST

Trial

U-ACHIEVE and CELEST

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 17:48

JAK1/2 inhibitor effective in alopecia areata

Presented By

James Cassella, Concert Pharmaceuticals, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 21:21

New and emerging atopic dermatitis therapies

Presented By

Prof. David Cohen, New York University School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:43

JAK inhibitors: a new therapeutic tool for dermatologists

Presented By

Prof. Brett King, Yale School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:08

JAK inhibitors: a pathogenesis-directed therapy for alopecia areata

Presented By

Prof. Brittany Craiglow, Yale University School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 19:10

Can JAK inhibitors close the current therapeutic gap in AD?

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:12

JAK-inhibitors: an emerging treatment option for vitiligo

Presented By

Prof. John Harris, University of Massachusetts, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 13:53

[Long Read] Current Look on Asthma

Presented By

Prof. Zuzana Diamant, Skåne University Hospital Lund, Sweden; University Medical Center Groningen, the Netherlands

Trial

COSMEX, COSMOS, BORA

Conference

ERS 2018

Type

Peer-reviewed article

7 November 2018 23:25